189359-65-7

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-NITRO-5-(TRIFLUOROMETHOXY)BENZOIC ACID is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Organic Synthesis:
2-NITRO-5-(TRIFLUOROMETHOXY)BENZOIC ACID is used as a reagent in organic synthesis for the production of dyes, pigments, and other fine chemicals, enhancing the range of colors and properties available in these industries.
Safety Precautions:
It is important to handle 2-NITRO-5-(TRIFLUOROMETHOXY)BENZOIC ACID with care, as it may be harmful if ingested, inhaled, or absorbed through the skin, and may cause irritation to the eyes and skin. Proper safety measures should be taken during its use and storage to minimize potential health risks.

Upstream product

• 1014-81-9 3-(trifluoromethoxy)benzoic acid 

Downstream Products

• 1426306-46-8 N-(2-nitro-5-trifluoromethoxy-benzoyl)-3-(2,2,2-trifluoroethylsulfanyl)-4-methyl-6-fluoro-aniline 
• 83265-56-9 2-amino-5-(trifluoromethoxy)benzoic acid 

Relevant academic research and scientific papers

Spiro-substituted pyrimido-cyclic compound, and preparation method and medical application thereof

The invention discloses a spiro-substituted pyrimido-cyclic compound with selective inhibition effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound or a prodrug thereof; the spiro-substituted pyrimido-cyclic compound is represented by a formula (I), and the definition of each group or symbol in the formula is shown in the specification in detail.In addition, the invention also discloses a pharmaceutical composition containing the compound and an application of the compound in preparation of cancer drugs.

QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS

This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.